US4339428A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
Assignee: Bristol Myers Co
•
Filing: 1981-06-18
•
Granted: 1982-07-13
•
Expires: 2001-06-18
Abstract
Abstract A capsule product preferably containing a high dosage of aspirin in powder or granulated form and at least one akaline tablet or pellet; the improvement in which said alkaline tablet or pellet comprises magnesium carbonate, calcium carbonate and a magnesium oxy component such as magnesium oxide, magnesium hydroxide or the combination of magnesium oxide and magnesium hydroxide. The alkaline tablet is preferably dimensioned so that it will contain a maximum amount of material in a minimum volume e.g. a spheroid so that it can be readily dropped into a gelatin capsule e.g. #0 gelatin capsule.
Inventors
- 👤 Thomas M. Tencza
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 11:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/60; A61K33/00; A61K33/06; A61K33/08; A61K33/10; A61K9/00; A61K9/48; A61K9/4808
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
145 words
As a unit dosage form a capsule having incorporated therein at least one alkaline tablet and an aspirin mixture; said aspirin mixture being present in said capsule as a powder or granulated material; said alkaline tablet comprising a combination of calcium carbonate, magnesium carbonate and a magnesium oxy component selected from the group consisting of magnesium oxide, magnesium hydroxide and a mixture of magnesium oxide and magnesium hydroxide; the aspirin being present in said capsule at a level of from 325 mg. to about 650 mg.; said capsule being dimensioned so that it may be conveniently swallowed and at the same time is not too small to accomodate effective amounts of capsule ingredients; said alkaline tablet being dimensioned so as to conveniently fit into said capsule; said powder or granulated material being essentially free of antacid and said alkaline tablet being essentially free of aspirin.
Claim 2
Dependent Claim
145 words
As a unit dosage form a capsule having incorporated therein at least one alkaline tablet and an aspirin mixture; said aspirin mixture being present in said capsule as a powder or granulated material; said alkaline tablet comprising a combination of calcium carbonate, magnesium carbonate and a magnesium oxy component selected from the group consisting of magnesium oxide, magnesium hydroxide and a mixture of magnesium oxide and magnesium hydroxide; the aspirin being present in said capsule at a level of from 325 mg. to about 650 mg.; said capsule being dimensioned so that it may be conveniently swallowed and at the same time is not too small to accomodate effective amounts of capsule ingredients; said alkaline tablet being dimensioned so as to conveniently fit into said capsule; said powder or granulated material being essentially free of antacid and said alkaline tablet being essentially free of aspirin.
Claim 3
Dependent Claim
38 words
A unit dosage form according to claim 1 wherein the quantity of alkaline material contained in the capsule is between about 20% to about 150% by weight based on the total weight of aspirin contained in the capsule.
Claim 4
Dependent Claim
52 words
A unit dosage form according to claim 2 in which said alkaline material, based on the weight of aspirin in the capsule comprises: (a) from about 5% to about 20% calcium carbonate; (b) from about 2% to about 10% magnesium carbonate; and (c) from about 2% to about 20% magnesium oxy component.
Claim 5
Dependent Claim
32 words
A unit dosage form according to claim 1 in which said aspirin is present in said capsule at a level in the range of from about 400 mg to about 650 mg.
Claim 6
Dependent Claim
39 words
A unit dosage form according to claim 4 in which the quantity of alkaline material contained in the capsule is between about 20% to about 150% by weight based on the total weight of the aspirin in said capsule.
Claim 7
Dependent Claim
52 words
A unit dosage form according to claim 5 in which said alkaline material based on the weight of aspirin in the capsule comprises: (a) from about 5% to about 20% calcium carbonate; (b) from about 2% to about 10% magnesium carbonate; and (c) from about 2% to about 20% magnesium oxy component.
Claim 8
Dependent Claim
17 words
A unit dosage form according to claim 6 in which said magnesium oxy component is magnesium oxide.
Claim 9
Dependent Claim
17 words
A unit dosage form according to claim 6 in which said magnesium oxy component is magnesium hydroxide.
Claim 10
Dependent Claim
23 words
A unit doage form according to claim 6 in which said magnesium oxy component is a mixture of magnesium oxide and magnesium hydroxide.
Claim 11
Dependent Claim
33 words
A unit dosage form according to claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 in which the aspirin is contained in said capsule at a level of about 500 mg.
Claim 12
Dependent Claim
22 words
A unit dosage form according to claim 1 in which at least one additional pharmaceutically active ingredient is contained in said capsule.
Claim 13
Dependent Claim
19 words
A unit dosage form according to claim 11 in which said additional pharmaceutically active ingredient is an additional analgesic.
Claim 14
Dependent Claim
18 words
A unit dosage form according to claim 11 in which said additional pharmaceutically active ingredient is a decongestant.
Claim 15
Dependent Claim
18 words
A unit dosage form according to claim 11 in which said additional pharmaceutically active ingredient is an antihistamine.
Claim 16
Dependent Claim
22 words
A unit dosage form according to claim 11 in which said additional active ingredients is a mixture of decongestant, antihistamine and antitussive.
Claim 17
Independent Claim
39 words
A method for alleviating pain and/or fever in a subject which comprises administering to said subject sufficient unit dosage forms defined in claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 to alleviate said pain and/or fever.
References Cited (Backward Citations)
CA593581A
Cited
FR808949A
Cited
US2224256A
Cited
US2447396A
Cited
US2698332A
Cited
GB754364A
Cited
US2918485A
Cited
US2889248A
Cited
US2801951A
Cited
GB827529A
Cited
US2888382A
Cited
US2990328A
Cited
US3019169A
Cited
US3323992A
Cited
GB1204580A
Cited
US3608064A
Cited
US4167558A
Cited
US4193985A
Cited
US4294819A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-07-12 | 1986-01-11 | 1986-07-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-07-12 | 1990-01-11 | 1990-07-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-07-12 | 1994-01-11 | 1994-07-13 | $7700.00 | Window Closed / Lapsed |